Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis Authors: Can Weng, Hao Deng, Ziyang Yang, Xi Zeng, Haoxuan Xu, Jiuru Li, Chunping Yu Published: 2025 ABSTRACT BackgroundBladder urothelial carcinoma (BUC) is one of the most common malignant tumors of the urinary system, and its drug resistance often leads to treatment failure and high mortality. Given the crucial role of tumor aerobic glycolysis in regulating drug resistance in BUC, elucidating its mechanisms is promising for developing novel therapeutic strategies against this clinical challenge.Main bodyIn this review, we provide a systematic description of the specific mechanisms through which tumor aerobic glycolysis regulates drug resistance of BUC, including improved DNA damage repair mechanisms, regulation of epigenetic changes, induction of tumor immune evasion, activation of resistance-promoting downstream mechanisms and increased drug efflux. Additionally, we discuss the potential of tumor aerobic glycolysis for clinical diagnosis and treatment of BUC.ConclusionsTumor aerobic glycolysis regulates drug resistance in BUC through multiple pathways. Future research should prioritize the development of biomarkers and targeted therapies against key enzymes and metabolites within these pathways to improve the diagnosis, treatment, and prognosis of drug-resistant BUC. Introduction Bladder urothelial carcinoma (BUC) is one of the most common urinary system malignancies. Currently, BUC has become the ninth most common cancer in the world, with approximately 613,000 new cases and 220,000 deaths worldwide in 2022 [1]. There are two main types of BUC: non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Of these, MIBC, which is highly aggressive and associated with a significantly poorer prognosis compared to NMIBC, accounts for about 25% [2]. Despite receiving the active treatment, including radical cystectomy and drug therapy, the five-year survival rate for MIBC patients is only 20–40% [2, 3]. The development of drug resistance is the main cause of death in BUC patients. Currently, cisplatin-based combination chemotherapy has become an important treatment for MIBC patients [3]. However, less than 30% of MIBC patients can achieve pathologic complete response (pCR) after drug treatment [4]. Furthermore, most BUC patients who are sensitive to drug treatment often eventually develop drug resistance [5]. The serious consequences of drug resistance emphasize the necessity and urgency of exploring the regulatory mechanisms behind BUC drug resistance. In recent years, tumor aerobic glycolysis has been widely considered to be closely related to the development of tumor resistance [6]. Tumor aerobic glycolysis, also known as the Warburg effect, refers to the metabolic process by which tumor cells switch from oxidative phosphorylation to aerobic glycolysis, which is characterized by high glucose uptake and massive lactate production [7]. Tumor aerobic glycolysis was significantly upregulated in drug-resistant BUC and showed significant correlation with therapy resistance [8]. Considering this close relationship between tumor aerobic glycolysis and BUC drug resistance, understanding the molecular mechanism behind this phenomenon is crucial to overcoming the development of BUC drug resistance. In this review, we summarize the mechanisms by which tumor aerobic glycolysis regulates BUC drug resistance, including improved DNA damage repair mechanisms, regulation of epigenetic changes, induction of tumor immune evasion, activation of resistance-promoting downstream mechanisms and increased drug efflux. Briefly, our discussion provides new insights into the potential regulatory mechanisms of drug resistance in BUC (Fig. 1). We believe this may provide potential solutions for the clinical diagnosis and treatment of drug-resistant BUC.Fig. 1The main mechanisms of tumor aerobic glycolysis regulating drug resistance in bladder urothelial carcinoma this diagram depicts the main steps of tumor aerobic glycolysis in bladder urothelial carcinoma cells. When glycolysis levels are upregulated in bladder urothelial carcinoma, it can promote drug resistance by regulating five mechanisms: DNA damage repair mechanisms, epigenetic changes, immune evasion, activation of resistance-promoting downstream mechanisms, and increased drug efflux. Generated using adobe Illustrator (version 26.3) The main mechanisms of tumor aerobic glycolysis regulating drug resistance in bladder urothelial carcinoma this diagram depicts the main steps of tumor aerobic glycolysis in bladder urothelial carcinoma cells. When glycolysis levels are upregulated in bladder urothelial carcinoma, it can promote drug resistance by regulating five mechanisms: DNA damage repair mechanisms, epigenetic changes, immune evasion, activation of resistance-promoting downstream mechanisms, and increased drug efflux. Generated using adobe Illustrator (version 26.3) Improved DNA damage repair mechanisms Tumor aerobic glycolysis mitigates DNA damage in BUC cells BUC cells employ tumor aerobic glycolysis as a key mechanism to counteract DNA damage and enhance drug resistance. Under normal physiological conditions, oxidative stress from reactive oxygen species (ROS) can induce DNA damage and trigger apoptosis. However, BUC cells have evolved sophisticated metabolic adaptations that effectively neutralize this threat through a coordinated network of antioxidant mechanisms. The cornerstone of this protective mechanism lies in the upregulation of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway (PPP). In BUC cells, heightened aerobic glycolysis drives G6PD overexpression, which catalyzes the conversion of glucose-6-phosphate (G6P) to NADPH. This metabolic reprogramming ensures abundant NADPH availability, which serves as the primary reducing cofactor for cellular antioxidant systems. The generated NADPH supports two major antioxidant pathways that collectively minimize oxidative DNA damage. First, NADPH fuels the thioredoxin (Trx)/thioredoxin reductase (TrxR) system, creating a robust antioxidant network. Second, it serves as an essential cofactor for glutathione reductase, enabling the regeneration of reduced glutathione (GSH) from its oxidized form (GSSG) (Fig. 2). The restored GSH then acts as a co-substrate for glutathione peroxidase, facilitating the detoxification of hydrogen peroxide and other peroxides into harmless water or alcohol [9]. Fig. 2Mechanisms of tumor aerobic glycolysis regulating DNA damage repair networks in bladder urothelial carcinoma aerobic glycolysis enhances DNA repair and chemoresistance through four integrated mechanisms. First, antioxidant defense and ferroptosis inhibition: PPP-derived NADPH fuels the GSH/GSSG and Trx/TrxR antioxidant systems to reduce oxidative DNA damage. G3P and LRRC45 stabilize NRF2 by disrupting KEAP1 binding, which promotes SLC7A11 transcription and cystine uptake for GSH synthesis. This enables GPX4 to suppress lipid peroxidation and inhibit cisplatin-induced ferroptosis. Second, apoptosis suppression: HK2–VDAC1 interaction prevents Bax-mediated DNA fragmentation, while nuclear PKM2 suppresses p53-PUMA pro-apoptotic signaling. Third, DNA repair pathway enhancement: repair capacity is augmented through ALDOA activation of ATM and DNA-PKcs for DSB repair, nucleotide derived from glycolysis precursors for DNA synthesis, and lactate-mediated promotion of both homologous recombination via MRE11 lactylation and non-homologous end joining via HDAC inhibition. Fourth, cell cycle checkpoint reinforcement: checkpoint control is strengthened through PKM2-cyclin D1/CDK4/6 activation, lactate-induced p21/p27 expression, and ATM-CHK2 signaling for damage surveillance. Generated using adobe Illustrator (version 26.3) Mechanisms of tumor aerobic glycolysis regulating DNA damage repair networks in bladder urothelial carcinoma aerobic glycolysis enhances DNA repair and chemoresistance through four integrated mechanisms. First, antioxidant defense and ferroptosis inhibition: PPP-derived NADPH fuels the GSH/GSSG and Trx/TrxR antioxidant systems to reduce oxidative DNA damage. G3P and LRRC45 stabilize NRF2 by disrupting KEAP1 binding, which promotes SLC7A11 transcription and cystine uptake for GSH synthesis. This enables GPX4 to suppress lipid peroxidation and inhibit cisplatin-induced ferroptosis. Second, apoptosis suppression: HK2–VDAC1 interaction prevents Bax-mediated DNA fragmentation, while nuclear PKM2 suppresses p53-PUMA pro-apoptotic signaling. Third, DNA repair pathway enhancement: repair capacity is augmented through ALDOA activation of ATM and DNA-PKcs for DSB repair, nucleotide derived from glycolysis precursors for DNA synthesis, and lactate-mediated promotion of both homologous recombination via MRE11 lactylation and non-homologous end joining via HDAC inhibition. Fourth, cell cycle checkpoint reinforcement: checkpoint control is strengthened through PKM2-cyclin D1/CDK4/6 activation, lactate-induced p21/p27 expression, and ATM-CHK2 signaling for damage surveillance. Generated using adobe Illustrator (version 26.3) Beyond these enzymatic antioxidant systems, BUC cells further amplify their protective capacity through transcriptional regulation. Nuclear factor erythroid 2-related factor 2 (Nrf2), as the main transcriptional regulator, enters the cell nucleus and then forms a heterodimer with small Maf transcription factors (sMaf), coordinating the expression of antioxidant genes and playing a crucial role in DNA damage response and drug resistance [10]. Importantly, recent evidence reveals a sophisticated regulatory crosstalk between tumor aerobic glycolysis and Nrf2 signaling. In normal cells, Keap1 binds to Nrf2 and promotes its ubiquitination and degradation, thereby maintains glycolysis and the PPP at normal metabolic levels. While in tumor cells, G3P accumulates as a result of enhanced aerobic glycolysis. This accumulation facilitates the S-lactoyl modification of cysteine residues in Keap1, which impairs its ability to bind Nrf2. Subsequently, Nrf2 translocates into the nucleus and activates the expression of antioxidant genes [11]. Besides G3P disrupting Keap1–Nrf2 binding, recent studies have also found that the centrosomal protein LRRC45 competes for Keap1, blocking Nrf2 ubiquitination and driving its nuclear import for antioxidant activation [12]. Together, these pathways illustrate a positive feedback mechanism between aerobic glycolysis and the Nrf2/antioxidant response elements (ARE) pathway in BUC cells [13]. This synergistic interaction substantially enhances cellular antioxidant capacity, resulting in measurable reductions in DNA damage markers including 8-oxoguanine (8-oxoG) and phosphorylated histone H2AX (γ-H2AX) [14] (Fig. 2). Notably, cisplatin could induce cell death in BUC cells through ferroptosis, a key mechanism driven by lethal lipid peroxidation [15]. However, this process can be counteracted by the activation of the Nrf2-ARE pathway, which confers protective resistance against cisplatin by inhibiting ferroptosis [16, 17]. Specifically, Nrf2 directly activates transcription of the System Xc (-) cystine/glutamate antiporter SLC7A11 upon nuclear entry [18]. After transcription is completed, SLC7A11 transfer to the cell membrane and mediates extracellular cystine uptake, which serves as the substance for GSH synthesis, ensuring continuous replenishment of the GSH pool. Concurrently, the substantial NADPH maintains the reduced state equilibrium of GSH/GSSG via glutathione reductase, providing abundant GSH as electron donors for the ferroptosis executor enzyme glutathione peroxidase 4 (GPX4) [19]. Subsequently, GPX4 block lipid peroxidation chain reactions and prevent ferroptosis [20] (Fig. 2). In addition, downregulation of Nrf2 is closely associated with reduced cisplatin resistance in BUC, as verified in clinical patient cohorts. This finding underscores the importance of Nrf2-mediated ferroptosis regulation in determining BUC treatment outcomes [21]. In summary, G3P-Keap1 and LRRC45 jointly mediate the Nrf2-SLC7A11–GPX4 axis, which participates in the inhibition of ferroptosis. Developing personalized treatment strategies based on tumor-specific antioxidant mechanisms may provide promising therapeutic avenues for BUC patients. In addition to directly regulating oxidative stress, BUC cells employ glycolytic enzymes to influence apoptotic signaling pathways and prevent DNA fragmentation through a series of interconnected mechanisms. Hexokinase 2 (HK2), which is highly expressed and serves as the rate-limiting enzyme in glycolysis, facilitates glucose phosphorylation and stabilizes mitochondrial membrane potential by interacting with the voltage-dependent anion-selective channel 1 (VDAC1) on the mitochondrial outer membrane [22]. The formation of the HK2–VDAC1 complex effectively inhibits membrane permeabilization mediated by Bcl-2-associated X protein (Bax) and the subsequent occurrence of DNA fragmentation [23]. Similarly, pyruvate kinase M2 (PKM2) is capable of translocating to the nucleus where it directly interacts with p53 [24], thereby suppressing the upregulation of pro-apoptotic genes such as the p53 up-regulated modulator of apoptosis (PUMA) [25], which has been verified through experiments on animals and patient cohorts (Fig. 2). These findings collectively suggest that the development of selective inhibitors targeting glycolytic enzymes or the disruption of these anti-apoptotic pathways could enhance the sensitivity of tumor cells to conventional therapies and help overcome treatment resistance. In the context of genomic stability maintenance, BUC cells mitigate DNA damage accumulation by utilizing glycolysis-enhanced cell cycle checkpoint monitoring systems. Typically, p53 plays a crucial role in maintaining genomic stability through the DREAM complex and retinoblastoma (RB) pathways, which down-regulate cell-cycle genes and facilitate G1/S arrest for DNA damage evaluation [26]. However, in BUC cells, the inactivation of p53 undermines this checkpoint function [27, 28]. Notwithstanding, BUC cells in a hyperglycolytic state are capable of reactivating cell cycle checkpoint functions via alternative mechanisms that involve metabolic reprogramming. Specifically, PKM2 is upregulated through the action of hypoxia-inducible factor-1α (HIF-1α) within the hypoxic tumor microenvironment [29]. And experimental studies in mice have shown the upregulation of PKM2 facilitates glycolysis [30]. Meanwhile, PKM2 interacts with phosphorylated β-catenin, leading to the expression of cyclin-D1 [31]. This process allows cyclin D1 to associate with cell cycle-dependent kinases (CDK) 4 and 6, forming active complexes that enhance the functionality of the G1/S checkpoint. Furthermore, the aldolase, fructose-bisphosphate A (ALDOA) protein has been found to enhance the kinase activities of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and ataxia-telangiectasia mutated proteins (ATM), thereby playing a direct role in the repair of DNA double-strand breaks (DSB) [32–34]. After the ATM is activated, CHK2 is also rapidly phosphorylated and activated, performing checkpoint control at each phase of the cell cycle [35] (Fig. 2). This modulation strengthens DNA damage response (DDR) signaling pathways, thereby reinforcing checkpoint control during the S and G2/M phases. Lactate metabolism and ATP production from glycolysis also contribute further to genomic stability in BUC cells. Zhang et al. demonstrated that lactate generated by lactate dehydrogenase A (LDHA) within the glycolytic pathway influences histone modifications and alters the expression profiles of cell cycle regulators, notably increasing the expression of p21 and p27 [36]. This upregulation promotes cell cycle arrest and facilitates DNA repair. Furthermore, glycolysis sustains Wee1 kinase activity through the generation of abundant ATP, thereby inhibiting CDK1 activity and preventing damaged cells from prematurely entering mitosis [37] (Fig. 2). A preclinical study has demonstrated that simultaneous inhibition of glycolysis and the ATR/CHK1 pathway significantly increases genomic instability and overcomes platinum resistance in BUC cells, highlighting the clinical relevance of these glycolysis-dependent protective mechanisms [38]. This mechanism has been confirmed in experiments conducted on mice. Combined therapeutic strategies that target this glycolysis-cell cycle axis have shown promise in preclinical models for enhancing therapeutic sensitivity in BUC. The elucidation of glycolysis-enhanced cell cycle checkpoint mechanisms presents potential targets for novel treatment strategies, wherein dual-targeting approaches directed at both glycolytic pathways and DNA damage response mechanisms may synergistically overcome the adaptive resistance of BUC cells. Tumor aerobic glycolysis promotes DNA repair pathway in BUC cells The enhancement of DNA repair capacity through tumor aerobic glycolysis in BUC cells constitutes a pivotal mechanism for preserving genomic stability. This enhancement primarily occurs via the supply of essential precursors for DNA synthesis and repair. Aerobic glycolysis facilitates the production of ribose and NADPH, which are crucial for nucleotide synthesis via the PPP, thereby ensuring an adequate supply of raw materials necessary for DNA repair processes [34]. In BUC cells, increased aerobic glycolysis markedly boosts nucleotide synthesis and expedites the repair of DNA damage. The inhibition of G6PD has been shown to reduce nucleotide synthesis and significantly decrease cisplatin resistance in BUC cells, which is directly associated with a reduced capacity for DNA repair [39]. Furthermore, the glycolytic intermediate G3P can reversibly enter the non-oxidative PPP via transketolase (TKT) and transaldolase (TAL) to generate ribose-5-phosphate (R5P) [40, 41]. Subsequently, R5P is converted into ribonucleotides by phosphoribosyl pyrophosphate synthetase (PRPS) and further reduced to deoxyribonucleoside triphosphates (dNTPs) by ribonucleotide reductase (RNR), thereby supplying essential substrates for DNA synthesis and repair [42]. It is worth noting that RNR has been identified as a key mediator of acquired resistance to Palbociclib in BUC, and the use of RNR inhibitors can effectively counter this resistance [43]. Meanwhile, ATP generated through glycolysis acts as a phosphate donor for nucleoside diphosphate kinase (NDPK), an enzyme established to be ubiquitous in BUC cells, helping to maintain the GTP/ATP balance and supporting the function of DNA repair enzymes [44, 45] (Fig. 2). These findings propose that combined inhibition strategies targeting both glycolysis and nucleotide synthesis could be effective. In addition to providing nucleotides, aerobic glycolysis modulates specific DNA repair pathways via lactate-mediated mechanisms. The significant lactate production associated with the Warburg effect contributes to the acidic tumor microenvironment and is involved in post-translational modifications of DNA repair proteins. Notably, lactate plays a role in the lactylation of meiotic recombination 11 (MRE11), a crucial nuclease in the homologous recombination repair (HRR) pathway, which is responsible for detecting and repairing DNA damage [46]. Chen et al. demonstrated that the MRE11 protein undergoes lactylation modification by the CBP family of histone acetyltransferases at lysine 673 following DNA damage. This lactylation significantly enhances the recruitment of RAD51 and RPA, thereby improving HRR efficiency and conferring resistance to chemotherapy [47] (Fig. 2). Notably, a recent single-cell transcriptome analysis revealed that cisplatin-resistant BUC cells exhibit markedly elevated levels of H3K18la, which promotes the upregulation of key transcription factors YBX1 and YY1. These transcription factors play critical roles in DNA repair by enhancing the expression of repair-related genes such as PTEN and RAD51, and are implicated in the regulation of cisplatin resistance in BUC. This implies that a glycolysis-epigenetic-DNA repair crosstalk pathway may significantly contribute to drug resistance mechanisms in BUC, warranting further investigation [8]. Additionally, the glycolytic enzyme PKM2 directly participates in HRR regulation through phosphorylation-dependent mechanisms. Steven et al. reported that PKM2 is phosphorylated by ATM at threonine 328 in response to ionizing radiation and oxidative stress, resulting in the nuclear accumulation of phosphorylated PKM2 at T328. This promotes HRR-mediated double-strand break repair by phosphorylating C-terminal binding protein interacting protein (CtIP) at T126, thereby increasing CtIP recruitment and enhancing DNA end resection [48]. The augmentation of non-homologous end joining (NHEJ) repair constitutes a notable contribution of aerobic glycolysis to the DNA repair capacity in BUC cells. DNA-dependent protein kinases (DNA-PK) are integral to NHEJ and the maintenance of chromosomal telomere stability [49]. Research by Waldemar et al. has revealed that glycolytic byproducts, specifically L-lactic acid and D-lactic acid, act as histone deacetylase (HDAC) inhibitors. This action induces hyperacetylation of histones H3 and H4, thereby reducing chromatin density and enhancing accessibility during DNA repair processes [50]. Furthermore, treatment with lactic acid resulted in an approximate twofold increase in the expression of DNA ligase IV (LIG4) and ataxia telangiectasia-like syndrome protein (APTX), while also enhancing DNA-PK activity (Fig. 2). These effects collectively bolster the NHEJ repair capacity under hyperglycolytic conditions, which have already been verified through in-vivo experiments. Collectively, these findings show that BUC cells use aerobic glycolysis to enhance DNA repair and maintain genomic stability. This suggests it is promising to combine glycolysis inhibitors with DNA repair modulators to overcome chemoresistance and use metabolic profiling to develop personalized treatment strategies. Regulation of epigenetic changes Glycolytic modulation of DNA methylation in BUC chemoresistance In BUC, resistance to chemotherapy is frequently driven by metabolic shifts, particularly the modulation of DNA methylation by increased glycolysis under the control of the HIF-1α signaling axis. HIF-1α appears to exert critical regulatory functions in BUC particularly in Warburg effect [51]. Under hypoxic conditions, TET1-mediated active demethylation (5mC→5hmC) at the HIF-1α promoter region enhances its transcriptional activity, subsequently upregulating glycolytic genes such as pyruvate dehydrogenase kinase 1 (PDK1) [52]. This metabolic shift is mechanistically achieved through pyruvate dehydrogenase (PDH) phosphorylation, which suppresses pyruvate entry into mitochondrial TCA cycle, thereby redirecting metabolic flux toward lactate production. Building on glycolytic reprogramming, the elevated glycolytic flux further influences the epigenetic landscape by modulating DNMT3B-mediated methylation at the miR-145 promoter. This alteration leads to derepression of miR-145 expression, ultimately relieving its post-transcriptional suppression of KLF4 and PTBP1, two key regulators involved in hypoxia-induced cellular adaptation [53, 54]. KLF4 induces exon 10 alternative splicing to generate the pro-glycolytic PKM2 isoform, while PTBP1 facilitates nuclear-to-cytoplasmic shuttling of PKM2 mRNA. Their synergistic action maintains cytoplasmic PKM2 localization, thereby amplifying the tumor aerobic glycolysis in BUC cells [55, 56]. This glycolysis–epigenetic circuit not only reinforces metabolic plasticity but also contributes to chemoresistance in BUC, particularly against cisplatin. The clinical relevance of this HIF-1α-driven chemoresistance is strongly supported; for instance, studies have shown that cisplatin-resistant BUC exhibits elevated HIF-1α expression in in vivo models, an observation consistent with clinical findings where chemoresistant patient tissues show significantly higher levels of HIF-1α compared to chemosensitive ones [57]. Notably, recent studies have identified the natural compound berberine as a promising epigenetic modulator. Berberine has been shown to activate TET3, which in turn catalyzes demethylation of the miR-145 promoter, thereby restoring miR-145 expression and potentially reversing resistance phenotypes [58] (Fig. 3). Fig. 3Mechanisms of tumor aerobic glycolysis regulating epigenetic changes in bladder urothelial carcinoma the elevation of tumor aerobic glycolysis serves as the core driving force behind the epigenetic alterations in bladder urothelial carcinoma cells. Increased lactate levels regulate the expression of key enzymes such as HIF-1α, glut, and LDHA, which, in turn, influence the epigenetic landscape. This metabolic shift activates various lncRnas, including MALAT1 and UCA1, which regulate the expression of downstream targets involved in glucose metabolism. Furthermore, lactate-induced changes affect microRNA activity, such as miR-200 and miR-145, establishing a feedback loop that coordinates metabolic and epigenetic processes. The precise mechanisms by which aerobic glycolysis mediates these changes are still under investigation. Generated using adobe Illustrator (version 26.3) Mechanisms of tumor aerobic glycolysis regulating epigenetic changes in bladder urothelial carcinoma the elevation of tumor aerobic glycolysis serves as the core driving force behind the epigenetic alterations in bladder urothelial carcinoma cells. Increased lactate levels regulate the expression of key enzymes such as HIF-1α, glut, and LDHA, which, in turn, influence the epigenetic landscape. This metabolic shift activates various lncRnas, including MALAT1 and UCA1, which regulate the expression of downstream targets involved in glucose metabolism. Furthermore, lactate-induced changes affect microRNA activity, such as miR-200 and miR-145, establishing a feedback loop that coordinates metabolic and epigenetic processes. The precise mechanisms by which aerobic glycolysis mediates these changes are still under investigation. Generated using adobe Illustrator (version 26.3) Glycolysis-driven histone modifications promote chemoresistance in BUC In BUC, glycolysis bidirectionally modulates chromatin plasticity through histone post-translational modifications (PTMs), establishing therapeutic resistance (Fig. 3). This metabolism-driven chromatin remodeling is orchestrated by acetylome and methylome modifications that govern chromatin accessibility at loci encoding critical metabolic regulators. This regulation of chromatin state is also paramount for an effective DNA damage response, as the recruitment and function of repair machinery are contingent upon an open and permissive chromatin structure [59]. A representative mechanism illustrating this metabolic-epigenetic interplay involves the modulation of histone H1 by Aurora kinase A. Enhanced glycolytic flux induces Aurora kinase A-mediated phosphorylation of histone H1 at serine 27 (H1S27ph), triggering chromatin compaction and transcriptional silencing of SIRT3, a mitochondrial regulator and glycolysis suppressor. This epigenetic silencing reduces oxidative phosphorylation (OXPHOS) capacity, enforcing metabolic dependence on glycolysis and further promoting chemoresistance [60]. Pharmacological inhibition of Aurora A restores H3K9ac levels, reactivates SIRT3-dependent mitochondrial deacetylation, suppresses glycolysis, and resensitizes tumors. However, the spatiotemporal dynamics of these modifications remain elusive, particularly regarding metabolic fluctuation-mediated antagonism between H3K9ac and H3K27me3 [61]. Future investigations should employ live-cell imaging modalities to resolve real-time fluctuations in histone modifications under metabolic stress [52]. Conversely, enhanced glycolytic activity can promote EZH2-mediated H3K27me3, leading to epigenetic silencing of IGFBP3. The suppression of IGFBP3 derepresses the IGF-1 R/PI3K/AKT signaling axis, which in turn upregulates GLUT1 and HK2, thereby sustaining high glycolytic throughput and promoting drug resistance. Notably, tumors harboring KDM6A mutations exhibit hyperactivation of EZH2, rendering them particularly sensitive to EZH2 inhibitors that disrupt glycolysis and restore OXPHOS [62]. However, given that KDM6A mutations occur in only ~15% of bladder carcinomas, precision therapeutic strategies must integrate comprehensive molecular subtyping [63]. On another front, recent findings have uncovered an additional glycolysis-driven positive feedback loop involving DLGAP5, USP11, and MYC. Under elevated glycolytic activity, DLGAP5 expression is upregulated in BUC cells, which promotes the deubiquitination and stabilization of MYC protein via enhanced interaction with USP11, a deubiquitinase known to regulate MYC stability. Stabilized MYC, in turn, transcriptionally activates DLGAP5, reinforcing its own expression and amplifying glycolytic flux. This DLGAP5–USP11-MYC axis creates a self-perpetuating loop that drives MYC accumulation and contributes to metabolic reprogramming and chemoresistance in BUC [64–66] (Fig. 3). The oncogenic role and clinical relevance of DLGAP5 are supported by evidence from both in vivo models and clinical samples; analysis of patient tissues shows DLGAP5 expression is substantially increased in BUC, where it positively correlates with higher clinical stage and poorer prognosis [65]. Glycolysis-mediated lncRNA regulation drives chemoresistance in BUC In BUC, glycolysis not only serves as the predominant energy production pathway but also drives therapeutic evasion and drug resistance through dynamic modulation of long non-coding RNA (lncRNA) expression and functionality (Fig. 3). The hyperactivated glycolytic flux within TME activates or stabilizes oncogenic lncRNAs via multiple mechanisms, thereby establishing coupled chromatin remodeling and metabolic reprogramming. One illustrative example involves the glycolysis-induced upregulation of MALAT1. Enhanced glycolysis transcriptionally upregulates MALAT1, which recruits SUZ12 to activate PRC2 complexes, depositing repressive H3K27me3 marks at E-cadherin promoters. This epigenetic silencing suppresses epithelial marker expression, induces epithelial-mesenchymal transition (EMT), and facilitates tumor progression. Concurrently, this remodeling amplifies Snail1 transcriptional activity, upregulating LDHA and monocarboxylate transporter 4 (MCT4) to promote lactate generation and microenvironment acidification, collectively establishing chemoresistance barriers [67, 68]. Furthermore, glycolytic amplification indirectly stabilizes UCA1 expression through kinase signaling activation. Functioning as a competing endogenous RNA (ceRNA) for miR-145, UCA1 sequesters miR-145 to relieve its suppression of HMGB1, thereby activating TLR4/NF-κB signaling (Fig. 3). This cascade upregulates autophagy-related genes, sustaining glycolysis-dependent survival through HMGB1-mediated nutrient recycling [69]. Conversely, suppressing hyperactive glycolysis maintains tumor-suppressive lncRNA MEG3 expression. MEG3 stabilizes p53 signaling to activate PUMA/BAX-mediated apoptosis while inhibiting LC3-II-dependent autophagy, effectively reversing glycolytic-driven chemoresistance. However, under high glycolytic flux, MEG3 undergoes promoter hypermethylation-mediated silencing, disrupting the apoptosis-autophagy equilibrium. This epigenetic suppression enhances drug efflux and stabilizes chemoresistant phenotypes, constituting a molecular hallmark of poor prognosis in BUC patients [69]. Glycolysis-enforced chemoresistance via miRNA-Epigenetic circuitry in BUC In BUC, glycolysis emerges as a critical amplifier of therapeutic resistance through modulation of microRNA (miRNA) expression and function (Fig. 3). Glycolysis-dependent tumors enforce miR-145 silencing via DNA hypermethylation, unleashing KLF4 and PTBP1 as dual executors of metabolic reprogramming [56, 70]. Enhanced glycolysis induces KLF4 binding to the PKM promoter to enforce PKM2 isoform switching, while PTBP1 stabilizes PKM2 mRNA through 3‘UTR interactions. These synergistic actions elevate the PKM2/PKM1 ratio, maximizing glycolytic output and chemoresistance [55, 56]. Mechanistically, lactate generated by glycolysis-driven PKM2 stabilizes DNMT3B, perpetuating miR-145 promoter hypermethylation - a self-reinforcing cycle that consolidates glycolytic dependency [56]. Concurrently, glycolysis epigenetically restricts glycolysis-suppressive miRNAs: hypermethylation of miR-29 family promoters derepresses DNMT3-mediated silencing of tumor suppressors like FHIT, thereby eliminating constraints on glucose utilization [71]. Furthermore, the glycolysis-driven miR-200/ZEB1/Twist1 axis links glycolytic adaptation to EMT plasticity. Glycolytic activation suppresses miR-200, relieving ZEB1 inhibition and activating Twist1, which upregulates HIF-1α to transactivate GLUT1 and LDHA. This cascade couples EMT progression with lactate overproduction, establishing a feedforward loop between metabolic and invasive phenotypes [72] (Fig. 3). Crucially, this glycolytic reprogramming is not uniform, but is driven by distinct subpopulations within the highly heterogeneous landscape of BUC [73, 74]. Among these, bladder cancer stem cells (BCSCs) marked by CD44 have been identified as a core driver of chemoresistance, largely due to their intrinsic reliance on a high-glycolytic state to maintain stemness and evade apoptosis [75, 76]. The underlying molecular mechanism is beginning to be elucidated. Upon binding its ligand hyaluronan, CD44 signaling specifically regulate the LKB1/AMPKα pathway, thereby lifting the suppression of HIF-1α. As a master transcriptional regulator, stabilized HIF-1α then orchestrates the upregulation of key glycolytic genes, such as GLUT1 and LDHA, forcing a metabolic shift towards aerobic glycolysis [76]. This creates a self-reinforcing loop where a specific CSC subpopulation leverages a metabolic product to solidify its own drug-resistant epigenetic landscape [8]. While single-cell transcriptomics has been pivotal in inferring these metabolic states, emerging single-cell metabolomics technologies hold the promise of directly quantifying these functional metabolic signatures in resistant cells, offering unprecedented opportunities to uncover targetable vulnerabilities. Glycolysis-driven drug resistance via chromatin remodeler-mediated metabolic rewiring In BUC, glycolysis directly promotes chemoresistance by translating metabolic stress signals into pro-glycolytic transcriptional programs through chromatin remodeling complexes. Enhanced glycolytic flux hijacks SMARCA2, which is also referred to as BRM and functions as the core ATPase subunit of the SWI/SNF complex,, whose function is not only crucial for transcriptional regulation but also essential for the DNA damage response, as it remodels chromatin to expose DNA lesions for repair, through the oncogenic long non-coding RNA MIR4435-2HG [77]. This disruption prevents SWI/SNF complex assembly at the mTOR promoter, inducing chromatin decompaction and mTORC1 activation (Fig. 3). The glycolytic-driven mTORC1 subsequently phosphorylates and stabilizes HIF-1α, enforcing the transcriptional upregulation of a suite of key target genes critical for this metabolic rewiring, notably GLUT1, HK2, and LDHA [78–80]. The coordinated overexpression of these genes establishes a robust chemoresistant phenotype through a multi-faceted defense mechanism: upregulated GLUT1 expression increases glucose uptake, providing ATP to fuel anti-apoptotic pathways and drug efflux pumps [81]; HK2 directly suppresses the intrinsic apoptotic pathway targeted by cisplatin through its interaction with mitochondrial VDAC, while the LDHA-driven production of lactate enhances the repair of chemotherapy-induced DNA damage [82–84]. Notably, knockdown of MIR4435-2HG reverses this process, restoring cell cycle control, suppressing tumor growth, and attenuating glycolytic flux [85]. Concurrently, glycolytic amplification exacerbates drug resistance through BAF60a-mediated chromatin remodeling. Under glycolytic stimulation, BAF60a recruits AMPKα-activated SWI/SNF complexes to the GLUT1 promoter, enhancing chromatin accessibility and glucose transporter expression (Fig. 3). Conversely, BAF60a deficiency impairs glucose uptake, reduces glycolytic output, and suppresses tumor proliferation [86]. Induction of tumor immune evasion The inhibition of immune cell function from competitive metabolism Glucose metabolism reprogramming was once widely regarded as a specific metabolic pathway of tumor cells, which is of great significance for the tumorigenesis, proliferation and invasion of BUC cells. However, an increasing number of reports indicate that glucose metabolism reprogramming also exists in tumor-infiltrating immune cells, such as CD4+ T cells, effector T cells, macrophages, and DC cells, and is essential for their activation and immune function. In various cancer models, these tumor-infiltrating immune cells have been shown to reprogram glucose metabolism by taking up glucose in tumor tissue [87]. Moreover, glucose deficiency impairs the function of these immune cells. For example, reducing the activity of glycolytic enzymes to inhibit the glycolytic pathway of T cells can lead to their low responsiveness in tumor tissue [88]. When the glycolysis level of T cells increases, the activation, proliferation and survival of T cells are promoted, while the differentiation of Treg cells is inhibited [89]. (Fig. 4) Unfortunately, the shared metabolic demands of cancer cells and immune cells and the limited nutrients within tumor tissues lead to metabolic competition between tumor cells and these tumor-infiltrating immune cells [90]. Undoubtedly, this competition interferes with the immune function to a certain extent by limiting the ability of these tumor-infiltrating immune cells to obtain energy, thereby leading to tumor immune escape.Fig. 4Mechanism of tumor aerobic glycolysis mediating immune escape of bladder urothelial carcinoma cells bladder urothelial carcinoma cells can inhibit the ability of immune cells to take up glucose through competitive metabolism, thereby inhibiting the immune response. Meanwhile, tumor aerobic glycolysis directly regulates the expression of immune regulatory factors to regulate the drug resistance of bladder urothelial carcinoma, such as promoting the upregulation of PD-L1, G-CSF, and GM-CSF and inhibiting the expression of TNF-α, IRF, and CXCL10. In addition, the production of a large amount of lactic acid can also affect the immune function of immune cells. Generated using adobe Illustrator (version 26.3) Mechanism of tumor aerobic glycolysis mediating immune escape of bladder urothelial carcinoma cells bladder urothelial carcinoma cells can inhibit the ability of immune cells to take up glucose through competitive metabolism, thereby inhibiting the immune response. Meanwhile, tumor aerobic glycolysis directly regulates the expression of immune regulatory factors to regulate the drug resistance of bladder urothelial carcinoma, such as promoting the upregulation of PD-L1, G-CSF, and GM-CSF and inhibiting the expression of TNF-α, IRF, and CXCL10. In addition, the production of a large amount of lactic acid can also affect the immune function of immune cells. Generated using adobe Illustrator (version 26.3) Interestingly, the function of Treg cells, which also undergo glucose metabolism reprogramming in tumor tissues, is not inhibited by this metabolic competition. Instead, the immunosuppressive function of Treg cells appears to be activated and enhanced. (Fig. 4) Lactate, a byproduct of glycolysis, is thought to play a key role in this process [91]. However, the mechanism behind the behavior of Treg cells, which is different from other tumor-infiltrating immune cells, has not been fully elucidated. This is an important scientific issue that needs to be systematically explored. How to target cancer cell glycolysis while allowing immune cells to obtain energy through glycolysis may become an important research direction in the field of tumor metabolic therapy in the future. It is worth noting that existing research has provided some possible approaches. For example, by genetically manipulating immune cells to overexpress glycolytic enzymes or glucose receptors, or by specifically delivering glycolytic metabolites to immune cells, thereby avoiding competitive metabolism [92, 93]. Nonetheless, further pharmacological trials are required to ensure the efficacy and safety of these approaches in the treatment of drug-resistant BUC. Regulation of the expression of immunomodulatory molecules In addition to competitive metabolism, glycolysis can also induce tumor immune evasion by directly regulating the expression of immunomodulatory molecules. A great deal of research evidence shows that the tumor aerobic glycolysis pathway can directly regulate the expression of many immune regulatory molecules so as to promote the immune escape of tumor cells. Firstly, in tumor cells, highly activated aerobic glycolysis can promote HK2-dependent PD-L1 (also known as B7–H1) expression [94]. Numerous studies have shown that elevated PD-L1 levels in BUC cells are positively correlated with chemotherapy failure and a poor survival rate [95, 96]. Although targeting PD-L1 can improve the progression of BUC patients to a certain extent, it is always difficult to avoid the drug resistance in the end [97]. Simultaneously targeting of PD-L1 and HK2 may enhance the efficacy of PD-L1 blockade and overcome drug resistance in BUC. Secondly, when glycolytic levels were low, the expression levels of TNF-α were elevated and strongly associated with a survival benefit, but this survival benefit was attenuated in BUC patients with high glycolytic markers or GLUT1 expression levels [98]. This suggests that the glycolytic pathway may be a potential drug target for enhancing anti-tumor immune responses. In addition, abnormal activation of the glycolytic metabolic pathway was significantly correlated with the upregulation of G-CSF/CSF1 and GM-CSF/CSF2 (colony stimulating factors), which led to the immunosuppressive state in the TME [99]. High glycolytic activity in tumor cells is also associated with decreased levels of immunostimulatory molecules such as interferon regulatory factor 1 (IRF1) and CXC chemokine ligand 10 (CXCL 10) [100]. (Fig. 4) IRF1 is a key transcription factor in the IFN-γ signaling pathway, mediating IFN-γ signaling to enhance chemotherapy-induced cell death. Its downregulation impairs this pathway and promotes tumor immune evasion [101]. Notably, decreased IRF1 expression has been associated with resistance to immune checkpoint blockade therapy in patients with BUC [102]. In addition, studies show that low expression of CXCL10, a T cell chemoattractant, is significantly associated with a poor prognosis in BUC patients [103, 104]. This may be because downregulation of CXCL10 impairs T-cell localization within the TME, preventing them from effectively killing tumor cells. In recent years, BUC has been widely recognized as having a suppressive TME characterized by overexpression of immunomodulatory molecules [105]. However, the relationship between these overexpressed immunoregulatory molecules and tumor aerobic glycolysis in BUC has not been fully explored yet. It is worth noting that the existing organoid models of BUC can already simulate the TME of BUC very well [106]. By constructing the BUC organoid model to explore the specific mechanism by which tumor aerobic glycolysis regulates the expression of immunomodulatory molecules, it is expected to provide new strategies to overcome the current responsiveness of BUC immunotherapy. Effects of lactate on immune cells Competitive metabolism drives metabolic reprogramming in both BUC cells and tumor-infiltrating immune cells, resulting in lactate accumulation within the TME. As a key byproduct of aerobic glycolysis, lactate is widely present in the TME of BUC and is regarded as a diagnostic and detection biomarker for this cancer [107]. In fact, lactate plays a key role in the immune escape of BUC cells through multiple immunosuppressive pathways, ultimately leading to the development of treatment resistance: (a) Lactate, which is widely present in the TME, will be absorbed by T cells, thereby damaging the energy metabolism of T cells and accelerating their death, a phenomenon that has been validated in vitro and in vivo. Fortunately, when the lactate uptake process of T cells is blocked, these cells can regain their ability to kill cancer cells [108]. In addition, lactate is also associated with shortened lifespan of CD8+ memory T cells, as demonstrated in vitro and in tumor-bearing mouse models [109]. (b) In a TME with high lactate, Treg cells can exhibit an active proliferation state and normally function to suppress effector T cells, as evidenced by both in vitro tissue culture and in vivo mouse studies [110]. In addition, high lactate environment can enhance PD-1 expression of Treg cells and reshape the function and phenotype of Treg cells [91]. (c) Lactate can promote the transformation from M1 macrophages to M2 macrophages through epigenetic regulation, a phenomenon that has been validated in an in vivo model [111, 112]. (d) Lactate can change the differentiation phenotype of dendritic cells (DCs) and inhibit their antigen presentation function [113, 114]. It should be noted that the inhibitory effect of lactate on DCs also affects the activation of CD8+ T cells, a mechanism that has been confirmed using in vivo models [115]. (e) Lactate induces the apoptosis of natural killer (NK) cells and natural killer T (NKT) cells, leading to immune evasion of tumor cells. This pro-apoptotic effect has been validated in vivo [116, 117]. (f) Lactate drives the selective differentiation of myeloid-derived suppressor cells (MDSCs) by regulating arginase and iNOS, and promotes the development and recruitment of MDSCs via GM-CSF and IL-6 [118]. (Fig. 4) Furthermore, a single-cell transcriptomic analysis revealed an enrichment of MDSCs in recurrent BUC, suggesting that MDSCs mediate drug resistance in BUC [119]. Therefore, targeting the BUC-MDSC crosstalk may benefit BUC patients. Notably, this targeted therapeutic approach is being explored in clinical trials (NCT02903914, NCT03236935) that are investigating the potential of restoring arginine levels to enhance immunotherapy efficacy in BUC patients. In addition, it is worth mentioning that lactate accumulation during glycolysis-driven tumor immune evasion not only suppresses immune cells but also modulates drug resistance mechanisms like DNA damage repair and autophagy through histone and non-histone lactylation. Interestingly, although existing studies generally believe that the role of lactate in the TME is to exert immunosuppressive effects through various pathways, some research evidence in recent years has challenged this traditional cognition. In vivo and in vitro experiments have shown that lactate participates in and promotes the production of cytokines (such as IFNγ/IL-2/TNFα) by T cells, thereby enhancing the anti-tumor function of T cells [120]. In addition, lactate can maintain T cell stemness and improve long-term anti-tumor efficacy through epigenetic regulation [121, 122]. Furthermore, existing evidence suggests that whether lactate exerts immunosuppressive effects or pro-inflammatory effects may depend on the pH in the TME. Barbieri et al. found that CD8+ T cells exposed to lactate at physiological conditions (pH = 7.4) exhibited enhanced cytotoxicity, whereas this effect was reversed under acidic conditions (pH = 6.9) [121]. BUC cells with high glycolytic activity, like other solid tumor cells, release large amounts of lactate into the extracellular matrix. This process lowers the pH of the TME, thereby allowing the immunosuppressive effects of lactate to become dominant in BUC [123]. Given the pH-dependent dual role of lactate in regulating immune cell function, the targeted delivery of pH buffers or proton pump inhibitors to the TME represents a promising therapeutic strategy for BUC. Activation of resistance-promoting downstream mechanisms Promoting effect on epithelial–mesenchymal transition (EMT) EMT is a process in which epithelial cells transform into mesenchymal cells, which can reduce intercellular adhesion and promote cell motility [124]. Through EMT, tumor cells can acquire stronger proliferation, invasion and metastasis abilities, which are crucial for tumor cells to acquire drug resistance. In recent years, a large number of studies have shown that EMT can promote BUC cells to acquire drug resistance and distant metastasis through multiple pathways, and the occurrence of EMT is closely related to tumor aerobic glycolysis [125, 126]. Currently, tumor aerobic glycolysis has been widely considered one of the hallmarks of tumor cell EMT. Exploring the specific mechanism of tumor aerobic glycolysis inducing EMT will provide new strategies for the treatment of BUC and overcoming BUC drug resistance. In the process of inducing EMT, the tumor aerobic glycolysis pathway is first upregulated through the expression or activation of glycolysis-related active substances. The expression levels of GLUTs and various glycolysis-related enzymes including hexokinase (HK), phosphofructokinase 1 (PFK1), PKM2 and lactate dehydrogenase (LDH) are significantly upregulated [127]. Upregulation of these glycolysis-related active substances promotes tumor aerobic glycolysis and produces a large amount of lactate, which can induce and enhance EMT through lactate/lactylation crosstalk with stromal/endothelial cells and activation of the TGF-β signaling pathway [128]. Fortunately, reducing lactate production can reverse EMT in tumor cells, suggesting that lactate may be a promising immunometabolic target for cancer therapy [129]. Furthermore, these glycolytic enzymes can redistribute from the cytoplasm to the nucleus upon activation, inducing EMT through interactions with EMT-promoting transcription factors (TFs) [130, 131]. (Fig. 5A) Interestingly, the stimuli that induce EMT in tumor cells are similar to those that induce upregulation of aerobic glycolysis in tumors and the development of tumor glycolysis-related drug resistance. For example, ROS, high glucose concentration, and hypoxia have an inductive effect on upregulation of aerobic glycolysis in tumor cells and the development of EMT in tumor cells [132–134]. In addition, it is worth mentioning that although EMT is closely related to the tumor aerobic glycolysis pathway, the induction mechanism of EMT is not only related to glycolysis. Oxidative phosphorylation and lipid metabolism are equally important for the induction of EMT [135, 136]. Therefore, targeting the aerobic glycolysis pathway alone cannot completely inhibit EMT. It is necessary to combine other therapeutic approaches when targeting aerobic glycolysis in BUC.Fig. 5Mechanisms of tumor aerobic glycolysis regulating EMT and autophagy in bladder urothelial carcinoma (a) glycolytic enzymes can promote epithelial-mesenchymal transition (EMT) through redistribution to the nucleus, and can also enhance autophagy via multiple signaling pathways. Furthermore, glycolysis generates large amounts of lactate, which facilitates autophagy by promoting histone lactylation and lactylation of core autophagy proteins. Additionally, lactate contributes to EMT by activating the TGF-β pathway and mediating lactylation-related crosstalk with stromal and endothelial cells. (b) hypoxia, ROS, and low glucose promote glycolysis to induce autophagy through various mechanisms, whereas high glucose, through the YAP1/TAZ pathway, triggers glycolysis that ultimately inhibits autophagy. Generated using adobe Illustrator (version 26.3) Mechanisms of tumor aerobic glycolysis regulating EMT and autophagy in bladder urothelial carcinoma (a) glycolytic enzymes can promote epithelial-mesenchymal transition (EMT) through redistribution to the nucleus, and can also enhance autophagy via multiple signaling pathways. Furthermore, glycolysis generates large amounts of lactate, which facilitates autophagy by promoting histone lactylation and lactylation of core autophagy proteins. Additionally, lactate contributes to EMT by activating the TGF-β pathway and mediating lactylation-related crosstalk with stromal and endothelial cells. (b) hypoxia, ROS, and low glucose promote glycolysis to induce autophagy through various mechanisms, whereas high glucose, through the YAP1/TAZ pathway, triggers glycolysis that ultimately inhibits autophagy. Generated using adobe Illustrator (version 26.3) Induction and inhibition of autophagy Autophagy can maintain cell homeostasis by removing damaged organelles and proteins through the degradation capacity of lysosomal enzymes [137]. However, the function of autophagy is a double - edged sword, as it is involved in the occurrence and development of tumors. Autophagy can inhibit the transformation of normal cells into tumor cells, while it can also improve the metabolic adaptability of tumor cells and promote the progression of tumor cells [138]. Previously, autophagy dysregulation has been widely observed in BUC cells and has been associated with cancer progression and therapeutic resistance [139, 140]. Tumor aerobic glycolysis in tumor cells plays an important role in inducing autophagy. Various glycolytic enzymes in tumor cells, such as HK II, PKM, GAPDH and monocarboxylate transporter 1 (MCT1), can participate in the induction of autophagy. HK II inhibits the mTOR-S6K signaling pathway by interacting with mTOR, leading to the occurrence and enhancement of autophagy [141, 142]; PKM can mediate the upregulation of the core autophagy protein Beclin-1 and promote the activation of autophagy [143]; after GAPDH undergoes nuclear redistribution, that is, after it transfers from the cytoplasm to the nucleus, it can activate SIRT1 to induce autophagy [144]; the high expression of MCT1 can enhance the activation of the LKB1/AMPK signaling pathway to induce autophagy in tumor cells [145]. In addition, in tumor tissues, a large amount of lactate produced by aerobic glycolysis acts as a bridge between glycolysis and autophagy, and can directly induce autophagy by lactylation modification of a variety of core autophagy proteins (PIK3C3/VPS34, ULK1, UVRAG, etc.) or indirectly induce autophagy by promoting the upregulation of autophagy-enhancing proteins through histone lactylation modification [146, 147]. (Fig. 5A) In fact, tumor aerobic glycolysis does not always induce autophagy. In some cases, it also induces autophagy inhibition [127]. Glycolytic enzymes often induce autophagy inhibition by directly interacting with autophagy-related proteins. For example, phosphofructokinase-2/fructose-2,6-bisphosphatase3 (PFKFB3) physically interacts with autophagy machinery, specifically the UBA domain of p62/sequestosome-1. When overexpressed in tumor tissues, Pfkfb3 can induce autophagy inhibition [148]. In addition, some glycolytic enzymes can induce the inhibition of autophagy through specific pathways. For example, PKM2 can indirectly lead to autophagy inhibition by activating the PI3K/AKT/mTOR pathway [149]. Considering the dual role of glycolysis in both inducing and inhibiting autophagy in BUC, it is necessary to clarify the conditions that determine this switch. Herein, we propose a model to explain these seemingly contradictory effects. Hypoxia is a key factor determining whether glycolysis induces autophagy. Under hypoxic conditions, HIF-1α is significantly upregulated, enhancing glycolysis in BUC cells. This leads to AMPK activation and mTOR suppression, thereby promoting autophagy [82]. ROS levels also influences whether glycolysis induces or inhibits autophagy. It drives the nuclear redistribution of ROS-dependent GAPDH, activating SIRT1 and facilitating autophagosome formation [150]. Moreover, glucose concentration is another important factor modulating the glycolysis–autophagy interplay. High glucose concentration activates the YAP1/TAZ signaling pathway by inhibiting AMPK expression and promoting its phosphorylation, thereby reinforcing glycolysis-mediated inhibition of autophagy [151]. In contrast, low glucose concentration increases the AMP:ATP ratio, leading to AMPK activation, thereby enhancing the induction of autophagy by glycolysis [152]. (Fig. 5B) Compared with normal glucose treatment, high glucose treatment (25 mM) decreased the LC3A/B-II:LC3A/B-I ratio and increased Beclin-1 expression in T24 and UMUC-3 BUC cell lines, suggesting enhanced autophagy, while low glucose treatment (2.8 mM) had the opposite effect [151]. Notably, BUC cells typically reside in a TME characterized by hypoxia, ROS accumulation, and low glucose concentrations, which may explain why upregulation of glycolysis in BUC often induces autophagy. In addition, it remains unclear whether different BUC subtypes or chemotherapy approaches influence the switch between glycolysis-induced promotion and inhibition of autophagy, warranting further investigation. Increased drug efflux Increased drug efflux is one of the main reasons for drug resistance in BUC. Tumor aerobic glycolysis is believed to promote increased drug efflux in a variety of ways. Exploring the mechanism by which tumor aerobic glycolysis in BUC regulates drug efflux will help find new clinical strategies to overcome drug resistance in BUC. Tumor aerobic glycolysis in tumors can promote increased drug efflux by directly increasing the number of drug transporters, which actively pump chemotherapy drugs out of tumor cells to prevent excessive drug accumulation and damage to tumor cells [153]. The increase in drug transporters reduces the effectiveness of drug treatment and leads to drug resistance in tumor cells. ATP-binding cassette transporters (ABC transporters), an important protein family involved in BUC resistance, including P-glycoprotein (P-gp, also known as ABCB1), MDR-related protein 1 (MRP1, also known as ABCC1), and breast cancer resistance protein (BCRP, also known as ABCG2), all showed significant upregulation in resistant BUC cells [154]. Existing studies have shown that tumor aerobic glycolysis in tumors has pathways that can promote the high expression of these drug transporters. When the level of glycolysis in tumors is upregulated, it is often accompanied by an increase in the expression of HK2 [155]. HK2 upregulation promotes ABC transporter expression, whereas HK2 inhibition abrogates this effect (Fig. 6). However, how HK2 regulates the expression of ABC transporters is still unclear and needs further exploration [156]. In addition, interference with the drug transporter ABCC3 inhibited the glycolytic activity in BUC cells. Western blot results revealed that in human BUC cell lines 5637 and UMUC-3, the expression level of LDHA was significantly downregulated following ABCC3 knockdown. Meanwhile, ABCC3 knockdown also resulted in a reduction of glucose consumption by over 30% and a decrease in lactate production by more than 24% in both 5637 and UMUC-3 cells [157]. The relationship between tumor aerobic glycolysis and the upregulation of drug transporters may not be a one-way promoting relationship, but more likely a mutually reinforcing positive feedback process. Nonetheless, this needs further research and exploration.Fig. 6Mechanisms of tumor aerobic glycolysis regulating drug efflux in bladder urothelial carcinoma in bladder urothelial carcinoma cells, increased glycolysis promotes HK upregulation, which in turn promotes the increased expression of three drug efflux proteins, P-gp, MRP1 and BCR1, thereby promoting drug efflux. In addition, glycolysis generates a large amount of lactic acid, which is excreted into the extracellular matrix through MCT1/4, promoting a decrease in pH and promoting the dissociation of weakly alkaline drugs in the extracellular matrix. Generated using adobe Illustrator (version 26.3) Mechanisms of tumor aerobic glycolysis regulating drug efflux in bladder urothelial carcinoma in bladder urothelial carcinoma cells, increased glycolysis promotes HK upregulation, which in turn promotes the increased expression of three drug efflux proteins, P-gp, MRP1 and BCR1, thereby promoting drug efflux. In addition, glycolysis generates a large amount of lactic acid, which is excreted into the extracellular matrix through MCT1/4, promoting a decrease in pH and promoting the dissociation of weakly alkaline drugs in the extracellular matrix. Generated using adobe Illustrator (version 26.3) Tumor aerobic glycolysis can also affect drug efflux by changing pH. BUC cells with high glycolytic activity can produce a large amount of lactate. This lactate is expelled from the cell via specialized membrane transporters, such as MCT1 and MCT4, which are highly expressed in BUC cells [158]. Lactate excreted from cells lowers the extracellular pH from 7.35 (normal tissue) to approximately 6.8 (tumor tissue) [159]. The decrease in extracellular pH can induce the expression of P-gp, thereby promoting the excretion of chemotherapeutic drugs out of cells [160]. However, the mechanism by which the reduction of extracellular pH induces P-gp expression has not been elucidated. Furthermore, it is worth mentioning that the reduction of intracellular pH can downregulate the expression of P-gp, thereby reversing P-gp-mediated multidrug resistance [161]. In addition, the decrease in extracellular pH can also cause weakly alkaline chemotherapy drugs, such as doxorubicin (a chemotherapy drug commonly used in BUC patients), to be ionized in the low pH TME, thereby reducing their damage to cancer cells [162] (Fig. 6). Therefore, appropriately changing the pH values inside and outside BUC cells, that is, appropriately lowering the intracellular pH value while increasing the extracellular pH value, may become an effective measure for the supplementary treatment of BUC. Exploring how tumor aerobic glycolysis promotes increased drug efflux will not only help improve our understanding of tumor resistance mechanisms, but may also identify potential biomarkers and new therapeutic targets. However, research on both is relatively limited to date. Further experiments are needed, especially in mouse tumor models, combined with gene knockout or transgenic experimental methods, to explore the regulatory strategies between tumor aerobic glycolysis and drug transporters. Clinical significance of glycolysis in BUC Tumor aerobic glycolysis, a hallmark metabolic feature of BUC, enables cancer cells to survive, proliferate, and develop drug resistance. However, the high dependence of BUC on tumor aerobic glycolysis may also become its fatal weakness. Elucidating the links between tumor aerobic glycolysis and the development of drug resistance in BUC provides novel perspectives for developing clinical strategies to overcome treatment resistance. Notably, BUC is a highly heterogeneous disease. Variations in glycolytic activity exist among different molecular subtypes of BUC cells, which may influence their response to therapies. Studies have demonstrated that tumor aerobic glycolysis is a common feature in both NMIBC and MIBC, and it is more significant in MIBC [163]. Furthermore, through transcriptomic analysis of 1750 MIBC samples, Kamoun et al. identified six distinct molecular subtypes: luminal papillary, luminal nonspecified, luminal unstable, stroma-rich, basal/squamous, and neuroendocrine-like [164]. Among these, the basal/squamous and neuroendocrine-like subtypes exhibit higher glycolytic activity, which is associated with therapy resistance and poorer prognosis [165, 166]. Therefore, in future research exploring therapeutic strategies targeting tumor aerobic glycolysis, it is crucial to stratify patients based on BUC subtypes. This approach will help identify the patient populations most likely to benefit from such treatments, thereby improving treatment precision and efficacy. There are some key enzymes in the tumor aerobic glycolytic pathway, such as HK, PFK, and PK, which critically regulate the cellular glycolysis of BUC cells. Targeted inhibition of these key enzymes shows significant therapeutic potential for overcoming BUC drug resistance. 2-Deoxy-D-glucose (2DG) is a glucose analog that inhibits the glycolysis process through two mechanisms. On one hand, it competitively binds with HK to suppress glycolysis; on the other hand, after binding to HK, 2DG is phosphorylated into 2-DG-6P, and the accumulation of this product exerts negative feedback inhibition on HK activity. Thereby, 2DG significantly attenuates the regulatory role of glycolysis in BUC drug resistance [167]. Treatment with 2DG effectively suppresses proliferation and clonogenicity in BUC cells with upregulated aerobic glycolysis [168]. 3-Bromopyruvate (3-BrPA), an alkylating agent, demonstrates potent anticancer activity by inhibiting HK2, GAPDH, and LDH, effectively disrupting both glycolysis and mitochondrial oxidative phosphorylation. Specifically, 3-BrPA disrupts the HK2–VDAC1 interaction, weakening glycolysis-mediated suppression of DNA damage in cancer cells; it induces GAPDH pyruvylation, promoting nuclear translocation of the protein and leading to cell death via ubiquitination and degradation of nuclear proteins; and it acts as a weak substrate of LDH, being converted to 3-bromolactate to inhibit normal glycolytic progression [169]. In an in vitro study, it has been confirmed that 3-BrPA has significant metabolic inhibition in BUC cells [170]. PFK15, a selective PFKFB3 inhibitor, suppresses proliferation across multiple BUC cell lines. However, its underlying pharmacological mechanism remains unclear. In addition, PFK15 is believed to achieve an additive effect in inhibiting tumor cell growth when used in combination with LDHA inhibitors [171]. Shikonin, a natural PKM2 inhibitor, impedes glycolytic ATP production by suppressing the HIF-1α/PKM2 pathway, leading to antiproliferative and pro-apoptotic effects in T24 BUC cells [172, 173]. Although some novel drugs targeting glycolysis are undergoing clinical trials (Table 1), it should be noted that there are still crucial challenges in developing glycolysis - targeted therapies for clinical application. Current inhibitors targeting BUC cells, such as 3-BrPA and shikonin, lack sufficient pharmacological validation and require further clinical trials. Meanwhile, their potential for off-target effects raises significant concerns. For instance, a clinical study (NCT00633087) demonstrated that 2-DG activates the PI3K/Akt signaling pathway, thereby inducing autophagy in cancer cells as a resistance mechanism to its therapeutic action [177, 178]. It would be worthwhile to investigate combination therapies of 2-DG with autophagy inhibitors in future studies. Another major challenge in treating BUC is its metabolic plasticity. A recent study demonstrated that BUC cells can enhance OXPHOS activity in response to therapy, thereby counteracting glycolytic inhibition [179]. Addressing this metabolic plasticity requires the implementation of dynamic metabolic monitoring and adaptive treatment strategies. Given these multifaceted challenges, future research should prioritize the development of combination therapies and dual/multi-target agents that simultaneously address glycolytic pathways and other resistance mechanisms.Table 1Summary of clinical trials in cancer with novel pharmaceutical agents targeting tumor aerobic glycolysisAgentTargetCancer typesNumber of clinical trialsStudy typesPhaseReference or NCTnumber2-DGHK2Prostate cancer1InterventionalPhase I/IINCT00633087Osteosarcoma,Lung cancer,Breast cancer,Pancreatic cancer,Head and neck cancer,Gastric cancer1InterventionalPhase INCT00096707LonidamineHK2Breast cancer1InterventionalPhase III[174]Ovarian cancer2InterventionalPhase II[175, 176]ATOHK2Ovarian cancer,Endometrial cancer1InterventionalPhase I/IINCT04489706Prostate cancer1InterventionalPhase IVNCT00004149AT-101LDHABreast cancer1InterventionalPhase IINCT06133088Adrenocortical carcinoma1InterventionalPhase IINCT00848016Glioblastoma2InterventionalPhase I/IINCT00540722NCT00390403Leukemia4InterventionalPhase I/IINCT00286780NCT00275431NCT01003769NCT01265199Prostate cancer4InterventionalPhase I/IINCT00286793NCT00286806NCT00666666NCT00571675Lung cancer7InterventionalPhase I/II/IIINCT00988169 NCT00934076NCT00397293NCT00544960NCT00773955NCT00544596NCT01977209Esophageal cancer1InterventionalPhase I/IINCT00561197Gastroesophageal junction cancer1InterventionalPhase I/IINCT00561197Lymphoma4InterventionalPhase I/IINCT05338931NCT00275431NCT00440388NCT00891072Laryngeal cancer1InterventionalPhase I/IINCT01633541Myeloma1InterventionalPhase I/IINCT02697344Squamous cell carcinoma of the head and neck1InterventionalPhase IINCT01285635PFK-158PFKFB3Advanced solid tumors1InterventionalPhase INCT02044861AZD3965MCT 1Diffuse large B-cell lymphoma;1InterventionalPhase INCT01791595Burkitt’s lymphoma1InterventionalPhase INCT01791595 Table 1Summary of clinical trials in cancer with novel pharmaceutical agents targeting tumor aerobic glycolysisAgentTargetCancer typesNumber of clinical trialsStudy typesPhaseReference or NCTnumber2-DGHK2Prostate cancer1InterventionalPhase I/IINCT00633087Osteosarcoma,Lung cancer,Breast cancer,Pancreatic cancer,Head and neck cancer,Gastric cancer1InterventionalPhase INCT00096707LonidamineHK2Breast cancer1InterventionalPhase III[174]Ovarian cancer2InterventionalPhase II[175, 176]ATOHK2Ovarian cancer,Endometrial cancer1InterventionalPhase I/IINCT04489706Prostate cancer1InterventionalPhase IVNCT00004149AT-101LDHABreast cancer1InterventionalPhase IINCT06133088Adrenocortical carcinoma1InterventionalPhase IINCT00848016Glioblastoma2InterventionalPhase I/IINCT00540722NCT00390403Leukemia4InterventionalPhase I/IINCT00286780NCT00275431NCT01003769NCT01265199Prostate cancer4InterventionalPhase I/IINCT00286793NCT00286806NCT00666666NCT00571675Lung cancer7InterventionalPhase I/II/IIINCT00988169 NCT00934076NCT00397293NCT00544960NCT00773955NCT00544596NCT01977209Esophageal cancer1InterventionalPhase I/IINCT00561197Gastroesophageal junction cancer1InterventionalPhase I/IINCT00561197Lymphoma4InterventionalPhase I/IINCT05338931NCT00275431NCT00440388NCT00891072Laryngeal cancer1InterventionalPhase I/IINCT01633541Myeloma1InterventionalPhase I/IINCT02697344Squamous cell carcinoma of the head and neck1InterventionalPhase IINCT01285635PFK-158PFKFB3Advanced solid tumors1InterventionalPhase INCT02044861AZD3965MCT 1Diffuse large B-cell lymphoma;1InterventionalPhase INCT01791595Burkitt’s lymphoma1InterventionalPhase INCT01791595 Summary of clinical trials in cancer with novel pharmaceutical agents targeting tumor aerobic glycolysis Osteosarcoma, Lung cancer, Breast cancer, Pancreatic cancer, Head and neck cancer, Gastric cancer Ovarian cancer, Endometrial cancer NCT00540722 NCT00390403 NCT00286780 NCT00275431 NCT01003769 NCT01265199 NCT00286793 NCT00286806 NCT00666666 NCT00571675 NCT00988169 NCT00934076 NCT00397293 NCT00544960 NCT00773955 NCT00544596 NCT01977209 NCT05338931 NCT00275431 NCT00440388 NCT00891072 Moreover, given the significant role of lactate generated by tumor aerobic glycolysis in modulating drug resistance in BUC, targeting lactate-associated pathways holds substantial clinical promise. Inhibiting lactate production and transport represents potential therapeutic strategies. AT-101 (gossypol) and Oxamate, two LDH inhibitors, have demonstrated efficacy in suppressing lactate synthesis to exert potent antitumor effects [180, 181]. Additionally, AZD3965, a MCT-targeting agent, partially reverses tumor drug resistance by blocking lactate efflux [182]. Notably, AZD3965 has exhibited favorable patient tolerability in a Phase I clinical trial (NCT01791595). Enhancing lactate oxidation may also present a viable therapeutic approach. Lithium carbonate (LC), a drug widely used to treat mental illness, has been shown to amplify CD8+T cell-mediated antitumor immunity by promoting lactate oxidation in tumor tissues [183]. Lactate oxidase (LOx) represents another emerging therapeutic candidate [184]. Despite the immense potential of lactate-targeted therapies, most remain in preclinical phase, necessitating further translational studies. Elucidating the mechanism by which tumor aerobic glycolysis regulates BUC drug resistance also brings new possibilities for the clinical diagnosis of BUC. Glycolysis-associated enzymes such as HK, PFK, and LDH are markedly upregulated in BUC cells. Through metabolomics and single-cell omics analyses, multiple glycolytic enzymes have been identified as potential BUC biomarkers [8]. Higher specificity is expected to be achieved by detecting the expression levels of these glycolysis-related enzymes in urine cells. Furthermore, it is promising to establish BUC risk prediction models and BUC prognostic models through these biomarkers. Future perspectives Despite significant advances in understanding how tumor aerobic glycolysis modulates BUC drug resistance, several knowledge gaps remain. First, non-metabolic functions of glycolytic intermediates and enzymes may harbor potential mechanisms regulating drug resistance. For instance, GAPDH, an enzyme metabolizing G3P, exhibits non-metabolic functions including interactions with chromatin-associated proteins and enhanced DNA repair through nuclear translocation regulation [185]. This suggests that glycolytic intermediates and enzymes may possess signaling regulatory roles beyond metabolism, warranting systematic exploration of their potential roles in DNA damage responses. Selectively modulating these interactions could sensitize BUC cells to chemotherapy without completely eliminating glycolysis, potentially reducing metabolic toxicity to normal tissues. Second, the gut microbiota-glycolysis-drug resistance axis represents another promising research area. Gut microbiota-derived short-chain fatty acids (SCFAs), particularly butyrate, influence the immune microenvironment of BUC via receptor-mediated pathways and may affect glycolysis levels through the gut-bladder axis [186, 187]. The unique characteristics of microbial communities in urogenital cancers also suggest their potential role in BUC development, though their association with the glycolysis-resistance axis requires systematic exploration [188]. Developing combination therapies based on microbial metabolites using patient-derived BUC organoids co-cultured with autologous microbiota may offer a novel, systematic strategy to overcome BUC resistance. Finally, integrating glycolytic biomarkers into precision medicine frameworks remains premature. Although multiple studies indicate that the expression of glycolysis-related proteins (GLUT1, HK2, PKM2) correlates with cancer invasiveness and poor prognosis [189–191], the practical value of these biomarkers for predicting patient stratification has not yet been systematically validated in prospective clinical cohorts. In the future, multicenter clinical trials employing standardized immunohistochemical scoring systems and metabolomics analysis to establish a BUC glycolytic subtype classification system may help identify patient subgroups most likely to benefit from glycolysis-targeted therapies, thereby realizing precision medicine based on metabolic phenotypes. Conclusion In the past few decades, drug therapy has become one of the important treatment options for BUC patients, including chemotherapy and immunotherapy [2]. However, most BUC patients who are sensitive to drug treatment eventually develop drug resistance [192]. Tumor aerobic glycolysis is highly active in BUC and is thought to regulate BUC drug resistance through multiple pathways. However, more research is needed on the regulatory mechanisms of tumor aerobic glycolysis. For example, histone lactylation levels are significantly increased in BUC and promote BUC drug resistance, but its regulatory mechanism for BUC drug resistance has not been fully elucidated [8]. Understanding the regulatory mechanisms of tumor aerobic glycolysis on BUC drug resistance, including improved DNA damage repair mechanisms, regulation of epigenetic changes, induction of tumor immune evasion, activation of resistance-promoting downstream mechanisms and increased drug efflux, may provide a more comprehensive understanding of BUC drug resistance and potential therapeutic strategies to overcome BUC drug resistance. To better illustrate the interactive network among different pathways, we have developed an integrative diagram depicting how key glycolytic components—such as PKM, lactate, and HK—orchestrate the five major resistance mechanisms in a synergistic manner. (Fig. 7) In addition, attention should be paid to the clinical application prospects of tumor aerobic glycolysis in the diagnosis, treatment and prognosis of drug-resistant BUC. It is necessary to actively carry out clinical research on glycolysis-related biomarker detection and glycolysis pathway targeted therapy.Fig. 7An integrative model depicting the central role of tumor aerobic glycolysis in regulating bladder urothelial carcinoma drug resistance this model proposes that in bladder urothelial carcinoma, the key glycolytic components PKM, lactate, and HK function as core regulatory nodes of tumor aerobic glycolysis, synergistically governing five major resistance mechanisms through interconnected pathways. It illustrates the convergence and crosstalk among these mechanisms: improved DNA damage repair mechanisms, regulation of epigenetic changes, induction of tumor immune evasion, activation of resistance-promoting downstream mechanisms and increased drug efflux. Generated using adobe Illustrator (version 26.3) An integrative model depicting the central role of tumor aerobic glycolysis in regulating bladder urothelial carcinoma drug resistance this model proposes that in bladder urothelial carcinoma, the key glycolytic components PKM, lactate, and HK function as core regulatory nodes of tumor aerobic glycolysis, synergistically governing five major resistance mechanisms through interconnected pathways. It illustrates the convergence and crosstalk among these mechanisms: improved DNA damage repair mechanisms, regulation of epigenetic changes, induction of tumor immune evasion, activation of resistance-promoting downstream mechanisms and increased drug efflux. Generated using adobe Illustrator (version 26.3)